secwatch.observer — SEC 8-K summary
======================================

Issuer:     InMed Pharmaceuticals Inc. (INM)
CIK:        0001728328
Form:       8-K
Filed at:   2024-11-15T23:59:59+00:00
Accession:  0001213900-24-098655
Event type: earnings
Sentiment:  positive
Materiality: 0.50
Item codes: 7.01, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

InMed Q1 FY2025 revenue $1.3M (+40% YoY); net loss narrows to $1.68M
--------------------------------------------------------------------

- BayMedica revenue $1.3M, up 40% YoY; BayMedica generated $0.3M net income (24% margin).
- Net loss narrowed to $1.68M ($2.17/sh) from $2.54M ($15.24/sh) in Q1 FY2024.
- Cash and equivalents $5.6M at Sep 30, 2024, down from $6.6M at June 30, 2024; expects cash to fund through Q1 calendar 2025.
- Reverse stock split effective Nov 14, 2024 to regain Nasdaq minimum bid price compliance.
- Preclinical data for Alzheimer's candidate INM-901 shows oral bioavailability and significant behavioral results; data expected Q4 2024.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024098655/0001213900-24-098655-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1728328/000121390024098655/ea0221397-8k_inmed.htm
  HTML page:      https://secwatch.observer/filing/0001213900-24-098655

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer